Syncona Share Discussion Threads

[brexitplus] 07/11/2018 15:10

Thanks Lux

Impressive presentation. With so much going on its hard to keep up!!!

[luxaeterna1] 07/11/2018 10:57

Thanks Brexitplus, I also noticed a September 2018 Autolus presentation on the Autolus page

[brexitplus] 02/11/2018 22:09

There is a Syncona presentation at the Numis Mid-Cap Conference dated 31/10/2018 on the Syncona website.

[luxaeterna1] 02/11/2018 11:08

hxxps://ash.confex.com/ash/2018/webprogram/Paper118050.html

Apparently the text overview of the Freeline paper on Haemophilia. Can't think how these two trials could have gone any better


"Results: As of 26 June 2018, two patients had been treated with FLT180a at the low dose of 4.5 x 1011 vg/kg and observed for 20 and 14 weeks, respectively. Within 4 weeks of receiving a single infusion of FLT180a, both patients achieved FIX levels of >30%, which is well within the mild haemophilia range where the risk of spontaneous bleeding is absent and bleeding occurs only after major surgery or injury. Patients 1 and 2 had peak FIX expression around Week 12 with levels of 48% and 66%, respectively. After the discontinuation of prophylactic steroids FIX levels stabilised at 46% and 48%, respectively.

No serious adverse events have been reported and there has not been any significant increase in liver enzymes. Prophylaxis with exogenous coagulation factor was stopped within the first week post FLT180a administration due to sufficient rise in patients endogenous FIX. Neither patient has required exogenous coagulation factor after this first week. No spontaneous bleeds have occurred. A traumatic bleed was reported by Patient 1 (right middle finger cut) at Week 10 but did not require treatment with FIX concentrates. The patient’s FIX activity at the time was 38%."

[luxaeterna1] 02/11/2018 11:01

Out of interest, what is the total addressable market for Haemophilia B? 100k patients globally?

[ltinvestor] 01/11/2018 22:42

Fc.I have a medical qualification and can appreciate the significance of these trial results , albeit only 2 patients but proof of concept has surely been confirmed....

[audigger] 01/11/2018 19:52

As proof of concept in humans goes, that's very encouraging

[thefartingcommie] 01/11/2018 19:30

i'm not in anyway medically qualified to comment on that one...my incredulity was directed at the trial consisisting of 2 people!...how is this 'truly extraordinary'?

[ltinvestor] 01/11/2018 19:06

Fc.The norm for FIX activity is 50 to 150% so to stabilise severly Ill patients at 48% is a real step forward....Do you not agree ?

[thefartingcommie] 01/11/2018 18:30

ps

The abstract notes that in the trial's first patient cohort:

· TWO patients with severe Haemophilia B received FLT180a at a single dose of 4.5 x 1011 vector genomes/kg body weight, which was well-tolerated with no serious adverse events.

· Within four weeks of infusion, FIX activity[1] in both participants rose to more than 30% and has since stabilised at 46% and 48%, respectively.[2]

tinvestor
1 Nov '18 - 17:00 - 187 of 188
0 0 0
The results from Freeline are truly extraordinary.A cure for haemophilia b is on the horizon and Syncona own 80% of Freeline......

lol....what is this?....are you being serious when you say this is ' truly extraordinary'...or just having a laugh?

[thefartingcommie] 01/11/2018 18:09

best not to get too excited ....its VERY early days here....and we all should remember Faron and the elusive cure for ARDS that never was .....or maybe uber short memories prevail here...;)

[ltinvestor] 01/11/2018 17:00

The results from Freeline are truly extraordinary.A cure for haemophilia b is on the horizon and Syncona own 80% of Freeline......

[luxaeterna1] 25/10/2018 11:50

It's in a channel, when newsflow arrives it tends to spike ~20% and the trend seems to be that it's edging slightly higher every time we get news.

There are a lot of news points due over the next 9 months. Various clinical trials reporting initial data and Blue Earth is expanding Axumin distribution quickly. I believe Axumin was approved for use in France a couple of weeks ago. Now available in:
Norway, Czech, Netherlands, UK, Austria and USA.

hxxp://www.blueearthdiagnostics.com/axumin-fluciclovine-18f-receives-positive-recommendation-from-transparency-committee-of-the-french-has-for-use-in-pet-imaging-of-suspected-recurrent-prostate-cancer/

[audigger] 24/10/2018 09:29

Back in at 249. A bounce back to 300 would be much appreciated

[thefartingcommie] 23/10/2018 10:11

alan@bj
8 Oct '18 - 17:06 - 179 of 183
0 0 0
The reverse would also be true, of course. As I see it, it depends on an individual's perception of the balance of risk and reward. If you to accept that the higher risk will bring greater reward,continue to hold.

If however you believe the higher risk will result in a significantly greater chance of loss, sell out and move on.............

indeed.....

[audigger] 11/10/2018 12:39

Well they are getting cheaper by the day but I have not yet bought back in as the markets could yet go a lot lower.

[thefartingcommie] 11/10/2018 09:45

lol..not a question of 'doing the work for me'...that was a semi rhetorical question...clearly I know the answer to both.

I posed those to you in response to your previous comment regarding 'it depends on an individual's perception of the balance of risk and reward.'

[alan@bj] 10/10/2018 16:34

Look it up yourself Fart. Why should I do the work for you?

[thefartingcommie] 10/10/2018 14:59

lol..

Greetings my friend (from Gan I believe)

well...seeing as you seem to be the resident expert in many stocks;)...

I wonder if you may be able to answer a couple of simple questions.

1) How many listed investment trusts on the London market only report the relevant NAV on a quarterly basis?

2) How many investments trusts on the London market are trading at a quoted 40% premium to last published NAV?

There you go...should'nt be to difficult for you,no words of more than 3 syllables..so you should be able to understand.(says he hopefully;)...0

[alan@bj] 08/10/2018 17:06

The reverse would also be true, of course. As I see it, it depends on an individual's perception of the balance of risk and reward. If you to accept that the higher risk will bring greater reward,continue to hold. If however you believe the higher risk will result in a significantly greater chance of loss, sell out and move on.

[douglas fir] 08/10/2018 13:39

."If that investment (or those two investments) were to fail, the impact on the Company following this change could be greater."


strangely inept timing of this announcement dont you think?

[brexitplus] 04/10/2018 10:47

DF

Looking at it the other way, they have huge confidence in success of Autolus, etc.

The fund change is interesting. They were tied to a number of investment companies that would handle funds for free. This happened when Syncona was BACIT and concentrated on cancer. Today the portfolio is much wider, the range of diseases are much wider, and better funds are available to generate cash for investment.

I see this as a positive move. I could be wrong.

[douglas fir] 04/10/2018 10:12

interesting read.


.."If that investment (or those two investments) were to fail, the impact on the Company following this change could be greater."

not entirely sure that is what I want to hear...given that Sync is trading at a huge premium already.

[brexitplus] 04/10/2018 07:39

Proposed change to the Investment Policy

In line with our strategy, we believe it is important that we have flexibility to support our life science portfolio companies to bring products to market, treatments to patients and deliver the best investment returns for our shareholders.

To provide greater flexibility, we propose to amend the life sciences investment requirements to the following:

No more than (measured at the time of an investment with respect to the impact of that investment):

– 35 per cent of the Company’s gross assets may be invested in any single life science investment;

– 60 per cent of the Company’s gross assets may be invested in the largest two life science investments; and

– 75 per cent of the Company’s gross assets may be invested in the largest three life science investments.

This change potentially brings additional risk to the Company and its shareholders. It would make it possible for further investment to be made even though the life science investment represented up to 35 per cent of the Company’s gross assets (compared to 25 per cent at present), or along with one other life science investment represented up to 60 per cent of the Company’s gross assets (compared to 50 per cent at present). If that investment (or those two investments) were to fail, the impact on the Company following this change could be greater.

However, we believe this proposed change draws an appropriate balance. It protects the ability of the Company to invest in its later stage businesses even if there are meaningful valuation movements, while continuing to restrict further investment (as at present) in the largest three assets if they exceed 75 per cent of the portfolio.

Other changes to the Investment Policy

We also wish to take the opportunity to propose a number of other updates to the Investment Policy. These are generally intended to reflect the evolution of its portfolio and to clarify areas of ambiguity, and include the change referred to below.

At present, the Investment Policy provides that the Company will seek (but is not required) to make fund investments in cases where the relevant investment manager provides investment capacity on a ‘gross return’ basis; meaning that the Company does not bear the impact of management or performance fees on the relevant investment. As the Company’s business has changed, and the investment parameters of the fund investments have evolved to support the life science portfolio, we believe it is important to have full flexibility to invest whether on a fee-paying or ‘gross return’ basis. The percentage of the fund investments invested on a gross return basis has declined to 55.7 per cent at 30 June 2018 and we expect this trend to continue as we further reposition the fund investments portfolio. We accordingly propose to update the Investment Policy to remove this requirement.

[brexitplus] 04/10/2018 07:10

Publication of EGM Circular to amend investment policy

04 October 2018

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, has today published a circular outlining a proposal to approve changes to the Investment Policy. The proposed changes would provide the Company with greater flexibility to support our life science portfolio companies and maximise investment returns for our shareholders.

Details of the proposed changes to the Investment Policy, the background to those changes, and the notice of an extraordinary general meeting ("EGM") to seek approval of a Special Resolution to approve the proposed changes are set out in the circular (the "EGM Circular"). The EGM will be held on 30th October 2018 at 10.30a.m.

The EGM Circular, together with the Form of Proxy for use at the EGM, is available electronically on Syncona's website and can be found here: hxxps://www.synconaltd.com/investors/document-library/. Printed copies of these documents are also being posted to shareholders where requested.